¿¼²©±¨°à ¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ÿÈÕÇ©µ½
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×Ü°æÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ ,e'r 0  
D;sG9Hky  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© J;sQvPHV8  
NSVE3  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© B4 bB`r  
<*vR _?!  
1.Co-stimulators (or co-stimulating molecules) KKwM\   
JCH9~n.  
2.NK-kB NG3?OAQTw  
G 1{m"1M  
3.Immunoglobulin superfamily SY95s  
7a[6@  
4.antigen-presenting cell (APC) BMq> Cj+  
Q 1i5"'][  
5.death domain 8B ,S_0!  
IAA_Ft  
6.CCR and CXCR ,wf_o%'eW  
JbEEI(Q>g  
7.Lectin (or mitogen) eNfH9l2k  
!I|_vJ@<  
8.Clusters of differentiation, CD) HRT NIx  
B<~AUf*y  
9.B7 family qKSR5 #  
#@nPB.  
10.Cytotoxic T lymphocyte, CTL) dkC_Sh{  
6l,6k~Z9  
11.IL-15 and IL-15 receptor (IL-15R) I!b"Rv=Nf-  
/ 1TK+E$  
12.MHC restriction )4o8SF7lz  
_I)TO_L;  
13.Affinity-chromatography S%H"i y  
zvN7aG  
14.Cyctosprin A, CsA Sj)?!  
=Crl{Ax  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) J_a2DM6d  
*s, bz.[  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© F.(W`H*1+  
m, +E5^  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 },<Y \  
n[BYBg1yG  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ nzO -\`40  
f:nXE&X[  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 @WXRZEz  
<bn|ni|c"  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© ;Ym6ey0t  
H [M:iV  
ÃâÒßѧרҵ£º 3p-SpUvp  
RYl{89  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ <`q-#-V@  
JFu.o8[Q  
Ïû»¯ÄÚ¿Æ£º  !#1UTa  
(w_b  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ /2r&ga&  
79Aa~+i'_  
ѪҺ²¡Ñ§×¨Òµ£º kQ[23  
R4D$)D  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÂÛ̳ÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»